Lipocine Inc. — FY2020 Form 10-K
Business context and reporting period. This annual report covers the year ended December 31, 2020; it is not a standalone fourth-quarter report. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products for metabolic and endocrine disorders. It had no product sales and was dependent on financing and licensing-related income.
Financial performance and position
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $165,000 |
| Research and development expense | $9.75 million | $7.47 million |
| General and administrative expense | $8.25 million | $5.60 million |
| Operating loss | $18.00 million | $12.90 million |
| Net loss | $20.96 million | $13.01 million |
| Basic and diluted loss per share | $0.38 | $0.50 |
| Cash used in operating activities | $15.30 million | $11.67 million |
- At year-end, cash and cash equivalents were $19.22 million, restricted cash was $5.00 million, and marketable securities were $0.45 million. Unrestricted cash, cash equivalents and securities totaled approximately $19.7 million.
- Total assets were $25.35 million; total liabilities were $10.01 million; stockholders’ equity was $15.34 million. Debt carrying value was approximately $5.59 million, including current and non-current portions. The SVB loan’s stated principal maturity schedule totaled $5.0 million, with maturity in June 2022 and a separate $650,000 final payment charge.
- No meaningful revenue margin can be assessed because the company reported no revenue in 2020. It reported an accumulated deficit of $172.0 million.
Material changes and notable items
- Net loss widened by about $8.0 million year over year. R&D increased 31%, mainly with LPCN 1144’s LiFT study and TLANDO manufacturing; G&A increased 47%, primarily due to legal costs.
- FY2020 included a $2.89 million non-cash loss from remeasuring warrant liability, versus a $236,000 gain in 2019. The warrant liability was $1.17 million at year-end, down from $4.59 million, after substantial warrant exercises. This fair-value movement materially affected net loss.
- Financing cash inflows were $20.90 million, including ATM/equity offering proceeds and $7.67 million from warrant exercises; cash and cash equivalents increased during the year. The company also reported a $234,000 PPP loan that was forgiven in November 2020.
- In January 2021, after year-end, Lipocine raised approximately $28.7 million gross from a public offering, before $1.9 million of offering costs. In February 2021, it amended its SVB loan agreement to remove the $5.0 million cash-collateral requirement.
Outlook, management commentary and risks
- TLANDO: The FDA granted tentative approval on December 8, 2020, concluding the product met quality, safety and efficacy standards. It was not final approval and could not be marketed in the U.S. before the Jatenzo exclusivity period expires March 27, 2022. The FDA required a black-box warning, including blood-pressure-related warnings, and post-marketing studies on medication-guide comprehension and adrenal insufficiency. Commercial plans under consideration include licensing, self-launch, or a launch with a partner.
- Pipeline: LPCN 1144’s 12-week Phase 2 results, announced in January 2021, showed liver-fat reductions and improvements in liver-injury markers; management expected 36-week biopsy data in Q3 2021. TLANDO XR had completed Phase 2 but needed further development, including food-effect work and Phase 3 planning. LPCN 1148’s IND was accepted for a planned Phase 2 study. LPCN 1107 development was subject to further FDA discussion after the proposed withdrawal of Makena; no pivotal study was expected to start in 2021 absent clarity or an out-license.
- Management estimated existing resources would fund projected operations through at least March 31, 2022, based on assumptions. It expected to need additional capital for ongoing operations and development. Financing may be unavailable or dilutive; failure to raise funds could force spending reductions, delays, or curtailment of operations.
- Key risks include dependence on TLANDO and its delayed market entry; testosterone-class safety concerns and competitive products; no established sales or market-access organization; clinical and regulatory uncertainty; single-source TU and capsule supply; dependence on contract manufacturers and research organizations; patent litigation with Clarus; and COVID-19-related disruption.
- The company’s lawsuit alleging Jatenzo patent infringement remained pending, with the jury trial postponed due to COVID-19. A securities class action also remained unresolved; management recorded no liability because loss was not considered probable or estimable. A separate derivative lawsuit was dismissed in July 2020.
- Auditors issued an unqualified opinion on the financial statements. Management reported disclosure controls and internal control over financial reporting effective as of December 31, 2020; the auditor did not provide an internal-control audit opinion.
Important facts for investors to verify
- Whether TLANDO obtains final FDA approval and can launch after the March 27, 2022 exclusivity date, including the impact of required warnings and post-marketing studies.
- Current cash runway and spending following the January 2021 offering, the release of restricted cash, debt service and planned clinical/commercial costs.
- Progress and full results of LPCN 1144’s 36-week biopsy assessment, and the evidence required for later-stage development.
- Outcomes and potential costs of the Clarus patent litigation and securities class action.
- Potential dilution from outstanding warrants, options, future ATM or equity financing, and the company’s limited authorized common-share capacity.